FDA Office Of Criminal Investigations Overhaul May Follow Director’s Exit
This article was originally published in The Gray Sheet
Executive Summary
The resignation of Terry Vermillion, the long-time head of FDA’s Office of Criminal Investigations, will give the agency a chance to thoroughly overhaul the office.
You may also be interested in...
People In Brief
New CDRH compliance director: Steve Silverman is the new director of the FDA device center's Office of Compliance, agency staffers informed "The Gray Sheet" Sept. 10. Silverman, who has been a senior advisor in the compliance office for the past year, takes the helm from long-time Compliance Director Tim Ulatowski, who will retire from the agency Jan. 1, 2011 (1"The Gray Sheet" May 3, 2010). For the remainder of the year, Ulatowski will advise Silverman and lead special projects in the office. Prior to joining CDRH, Silverman was assistant director of the drug center's Office of Compliance. He has also worked in FDA's Office of Chief Counsel
Hamburg Outlines Planned Reforms Of FDA Criminal Investigations Office
FDA Commissioner Margaret Hamburg outlined reforms planned for the agency's Office of Criminal Investigations, including new criteria for selecting misdemeanor prosecution cases against responsible corporate officials
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.